静止VSIG4通过调节JAK2/STAT3通路来抑制质母细胞瘤的生长
Congying Zheng1, Chengliang Mao1, Kai Tang1
1Department of Neurosurgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou City, Guangdong Province, People's Republic of China.
Neuropsychiatric disease and treatment
|June 9, 2023
概括
在质母细胞瘤 (GBM) 中抑制VSIG4促进细胞死亡,并通过影响JAK2/STAT3通路来抑制瘤生长. 这项研究揭示了治疗这种侵袭性脑癌的新治疗点.
科学领域:
- 神经瘤学神经瘤学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 质母细胞瘤 (GBM) 是成年人中最具攻击性的原发性脑瘤.
- 血管细胞粘附分子4 (VSIG4) 已与GBM发展有关.
- 了解VSIG4的调节机制对于向治疗至关重要.
研究的目的:
- 调查 GBM 中 VSIG4 的下游监管机制.
- 阐明VSIG4在GBM进展和细胞死亡中的作用.
- 探索针对VSIG4进行GBM治疗的潜力.
主要方法:
- 通过GEPIA和RT-qPCR分析的VSIG4表达.
- 通过转录组测序识别的下游目标.
- 使用西式涂抹和ELISA评估的热和JAK2 / STAT3通路.
- 在体外评估GBM细胞的增殖,迁移和入侵.
- 在异种移植小鼠模型中研究了瘤生长抑制.
主要成果:
- 在GBM组织中,VSIG4表达显著上调.
- VSIG4的淘汰抑制了GBM细胞的增殖,迁移和入侵.
- 沉默VSIG4在GBM细胞中促进了烧灭.
- 确定了JAK2/STAT3信号通路作为一个关键的下游媒介.
- 在体内研究证实,VSIG4 Knockdown抑制了GBM瘤的生长.
结论:
- VSIG4促进了GBM的进展,其沉默诱导了热.
- JAK2/STAT3通路是GBM中VSIG4的关键下游调节器.
- 准VSIG4为质母细胞瘤提供了一个有前途的治疗策略.
相关概念视频
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Experimental RNAi
6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


